• Grail published an ASCO poster on real-world use of its multi-cancer early detection blood test in a private primary care network.
• Analysis covered 2,930 tests in 1,952 patients from November 2021 to November 2025; first-test cancer signal detection rate was 1.02%.
• Among 13 patients without known cancer who tested positive with ≥12 months follow-up, 7 were later diagnosed with cancer; median time to diagnosis was 33 days.
• Cancer-signal origin predictions matched diagnosed cancer in 7 of 7 cases; 5 of 7 detected cancers lacked USPSTF grade A/B/C screening.
• Repeat-testing was common; 69.1% of 997 patients with >15 months follow-up received at least two tests, typically on an annual interval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.